YL
Larasati, Yonika Arum
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Pathogenic Gαo Mutants Drive Dominant GPCR Coupling in GNAO1 Encephalopathies | The FASEB journal |  | 2026 | 35 | 64 | ||
| Loss of the conserved switch III region in a G protein leads to severe pediatric encephalopathy | Science signaling |  | 2025 | 19 | 0 | ||
| Clinical-molecular profiling of atypical GNAO1 patients : Novel pathogenic variants, unusual manifestations, and severe molecular dysfunction | Genes & diseases | | 2025 | 39 | 29 | ||
| Atypical GNAO1 variants in severe childhood speech disorders: clinical, genetic, and molecular insights | Molecular autism | | 2025 | 12 | 16 | ||
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | | 2024 | 133 | 301 | ||
| Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation | Movement disorders | | 2024 | 101 | 174 | ||
| GNAO1 Mutations Affecting the N‐Terminal α‐Helix of Gαo Lead to Parkinsonism | Movement disorders | | 2024 | 117 | 229 | ||
| Personalized Drug Discoveries for Patients with GNAO1 Encephalopathies | | 2023 | 323 | 407 | |||
| Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R | Cells | | 2023 | 118 | 85 | ||
| In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening | Med | | 2023 | 137 | 1 | ||
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | | 2023 | 104 | 174 | ||
| Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn2+ in GNAO1 encephalopathy models | Science advances | | 2022 | 206 | 189 | ||
| Unlocking the Wnt pathway : therapeutic potential of selective targeting FZD7 in cancer | Drug discovery today | | 2021 | 548 | 534 |
